Literature DB >> 26311594

GFR Estimating Equations and Liver Disease.

Tomasz Beben1, Dena E Rifkin2.   

Abstract

It is important to accurately assess the glomerular filtration rate (GFR) of patients with liver disease to deliver care and allocate organs for transplantation in a way that improves outcomes. The most commonly used methods to estimate GFR in this population are based on creatinine, which is biased by these patients' low creatinine production and potentially by elevated serum bilirubin and decreased albumin levels. None of the creatinine-based estimated glomerular filtration rate (eGFR) equations have been specifically modified for a population with liver disease, and even measurement of a 24-hour creatinine clearance has limitations. In liver disease, all creatinine-based estimates of GFR overestimate gold standard-measured GFR, and the degree of overestimation is highest at lower measured GFR values and in more severe liver disease. Cystatin C-based eGFR has shown promise in general population studies by demonstrating less bias than creatinine-based eGFR and improved association with clinically important outcomes, but results in the liver disease population have been mixed, and further studies are necessary. Ultimately, specific eGFR equations for liver disease or novel methods for estimating GFR may be necessary. However, for now, the limitations of currently available methods need to be appreciated to understand kidney function in liver disease.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Estimated GFR

Mesh:

Substances:

Year:  2015        PMID: 26311594      PMCID: PMC4552961          DOI: 10.1053/j.ackd.2015.05.003

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  52 in total

1.  Limitations of compensated Jaffe creatinine assays in cirrhotic patients.

Authors:  Nils Kuster; Anne-Sophie Bargnoux; Georges-Philippe Pageaux; Jean-Paul Cristol
Journal:  Clin Biochem       Date:  2011-12-02       Impact factor: 3.281

2.  Renal function measurements from MR renography and a simplified multicompartmental model.

Authors:  Vivian S Lee; Henry Rusinek; Louisa Bokacheva; Ambrose J Huang; Niels Oesingmann; Qun Chen; Manmeen Kaur; Keyma Prince; Ting Song; Elissa L Kramer; Edward F Leonard
Journal:  Am J Physiol Renal Physiol       Date:  2007-01-09

3.  Glomerular filtration rate measurement in cirrhotic patients with renal failure.

Authors:  L Roy; L Legault; G Pomier-Layrargues
Journal:  Clin Nephrol       Date:  1998-12       Impact factor: 0.975

4.  Cystatin C versus creatinine in determining risk based on kidney function.

Authors:  Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

5.  Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome.

Authors:  S Demirtaş; A Bozbaş; A Akbay; Y Yavuz; L Karaca
Journal:  Clin Chim Acta       Date:  2001-09-25       Impact factor: 3.786

6.  Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better?

Authors:  Jillian MacAulay; Kara Thompson; Bryce A Kiberd; David C Barnes; Kevork M Peltekian
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

7.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

8.  Creatinine clearance: an inadequate marker of renal filtration in patients with early posthepatitic cirrhosis (Child A) without fluid retention and muscle wasting.

Authors:  N G DeSanto; P Anastasio; C Loguercio; L Spitali; C Del Vecchio Blanco; M Corvinelli; M Cirillo
Journal:  Nephron       Date:  1995       Impact factor: 2.847

9.  Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? .

Authors:  José M Ladero; María C Cárdenas; Luis Ortega; Andrea González-Pino; Francisca Cuenca; César Morales; Anna Lee-Brunner
Journal:  Ann Hepatol       Date:  2012 Sep-Oct       Impact factor: 2.400

10.  Serum cystatin-C is not superior to serum creatinine in predicting glomerular filtration rate in cirrhotic patients.

Authors:  Siavosh Nasseri-Moghaddam; Mohamad-Reza Ganji; Mohammad-Reza Kochari; Shahnaz Tofangchiha
Journal:  Middle East J Dig Dis       Date:  2013-10
View more
  15 in total

1.  New Organ Allocation System for Combined Liver-Kidney Transplants and the Availability of Kidneys for Transplant to Patients with Stage 4-5 CKD.

Authors:  William S Asch; Margaret J Bia
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-27       Impact factor: 8.237

Review 2.  Methods of Estimating Kidney Function for Drug Dosing in Special Populations.

Authors:  Laura A Hart; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

3.  [Laboratory tests for kidney disease].

Authors:  G M Fiedler; B Vogt
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

4.  REnal Flow and Microstructure AnisotroPy (REFMAP) MRI in Normal and Peritumoral Renal Tissue.

Authors:  Andrea L Liu; Artem Mikheev; Henry Rusinek; William C Huang; James S Wysock; James S Babb; Thorsten Feiweier; David Stoffel; Hersh Chandarana; Eric E Sigmund
Journal:  J Magn Reson Imaging       Date:  2018-01-13       Impact factor: 4.813

Review 5.  Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis.

Authors:  Lukas Otero Sanchez; Claire Francoz
Journal:  United European Gastroenterol J       Date:  2021-02-16       Impact factor: 4.623

6.  Feasibility Study of NMR Based Serum Metabolomic Profiling to Animal Health Monitoring: A Case Study on Iron Storage Disease in Captive Sumatran Rhinoceros (Dicerorhinus sumatrensis).

Authors:  Miki Watanabe; Terri L Roth; Stuart J Bauer; Adam Lane; Lindsey E Romick-Rosendale
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

7.  Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?

Authors:  Pierre Delanaye; Natalie Ebert; Toralf Melsom; Flavio Gaspari; Christophe Mariat; Etienne Cavalier; Jonas Björk; Anders Christensson; Ulf Nyman; Esteban Porrini; Giuseppe Remuzzi; Piero Ruggenenti; Elke Schaeffner; Inga Soveri; Gunnar Sterner; Bjørn Odvar Eriksen; Sten-Erik Bäck
Journal:  Clin Kidney J       Date:  2016-08-23

Review 8.  Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate.

Authors:  Ahmed Alaini; Deepak Malhotra; Helbert Rondon-Berrios; Christos P Argyropoulos; Zeid J Khitan; Dominic S C Raj; Mark Rohrscheib; Joseph I Shapiro; Antonios H Tzamaloukas
Journal:  World J Methodol       Date:  2017-09-26

9.  Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?

Authors:  Pierre Delanaye; Toralf Melsom; Natalie Ebert; Sten-Erik Bäck; Christophe Mariat; Etienne Cavalier; Jonas Björk; Anders Christensson; Ulf Nyman; Esteban Porrini; Giuseppe Remuzzi; Piero Ruggenenti; Elke Schaeffner; Inga Soveri; Gunnar Sterner; Bjørn Odvar Eriksen; Flavio Gaspari
Journal:  Clin Kidney J       Date:  2016-09-09

10.  Clinical characteristics of sepsis-induced acute kidney injury in patients undergoing continuous renal replacement therapy.

Authors:  A Young Cho; Hyun Ju Yoon; Kwang Young Lee; In O Sun
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.